vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
Healthcare
$16.36 +1.47%
+$0.50 today
- Market cap
- $64.69M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
52W Low $14.00High $44.00
Volume 0.02M
Average 0.05M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$32.81M
FY 2025 · Annual
Net Income
-$26.97M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.01M | 2.02M | 0 | 1.02M | 0 |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — |
| Research & Development | 13.32M | 12.36M | 13.6M | 11.55M | 17.86M |
| Selling, General & Admin | 12.34M | 12.2M | 11.91M | 13.65M | 14.95M |
| Operating Expenses | 25.67M | 24.56M | 25.5M | 25.2M | 32.81M |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| EBITDA | (17.52M) | (24.77M) | (25.86M) | (22.52M) | (31.06M) |
| EBITDA Margin | -437.3% | -1227.3% | — | -2214.0% | — |
| Operating Income | (21.66M) | (22.54M) | (25.5M) | (24.18M) | (32.81M) |
| Operating Margin | -540.9% | -1116.9% | — | -2377.6% | — |
| Interest Income | 1K | 352K | 472K | 1.57M | 1.87M |
| Interest Expense | 12K | 15K | 13K | 0 | 6K |
| Other Income / Expenses | 4.05M | (2.33M) | (464K) | 1.58M | 1.73M |
| Income Before Tax | (17.62M) | (24.87M) | (25.97M) | (22.61M) | (31.08M) |
| Pre-Tax Margin | -439.9% | -1232.6% | — | -2222.7% | — |
| Income Tax Expense | 115K | 200K | 0 | 100K | 0 |
| Net Income | (12.99M) | (19.16M) | (20.25M) | (18.46M) | (26.97M) |
| Net Margin | -324.3% | -949.7% | — | -1815.3% | — |
| EPS (Basic) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| EPS (Diluted) | (8.29) | (9.98) | (9.71) | (3.20) | (3.20) |
| 1.57M | 1.92M | 2.08M | 5.77M | 8.42M | |
| 1.57M | 1.92M | 2.08M | 5.77M | 8.42M |
VTVT Earnings Waterfall · TTM
NASDAQ:VTVT · Revenue to Net Income
Key Ratios
EPS$0.02
Gross Margin25.0%
Net Margin16.4%
P/E Ratio-4.5
P/S Ratio2.3
Analysis
$36.8M of revenue converted into $2.3M of net income for the selected period. Gross margin is 25.0% and net margin is 16.4%, showing how much revenue survives after costs and taxes. EPS is $0.02, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 8, 2026 | |
| 8-K | Current report | Oct 6, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
How much revenue does VTVT generate?
vTv Therapeutics Inc. (VTVT) reported $0.00 of revenue in fiscal 2025.
Is VTVT profitable?
vTv Therapeutics Inc. (VTVT) reported -$26.97M of net income.
Continue the stock analysis
Jump to another research area for this company.